Oxidative stress-mediated neurodegeneration: A tale of two models

Neurodegeneration: Theory, Disorders and Treatments

Volumn , Issue , 2011, Pages 1-44

  Wong, Paul K Y ^a   Kim, Jeesun ^a   Kim, Soo Jin ^a   Kuang, Xianghong ^a   Lynn, William S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895222348     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (265)

1. Bensaad, K; Vousden, K. Savior and slayer: the two faces of p53. Nat Med, 2005, 11, 1278-9.
2. Limoli, CL; Radoslaw, R; Giedzinski, E; Mantha, S; Huang, TT; Fike. JR. Cell-density-dependent regulation of neural precursor cell function. Pro. Natl. Acad. Sci., USA, 2004, 101, 16052-16057.
3. Ito, K; Hirao, A; Arai, F; Takubo, K; Matsuoka, S; Miyamoto, K; Ohmura, M; Naka, K; Hosokawa, K; Ikeda, Y; Suda, T. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med, 2006, 12, 446-51.
4. Rhee, SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science, 2006, 312, 1882-3.
5. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 2001, 18, 685-716.
6. Lombard, DB; Chua, KF; Mostoslavsky, R; Franco, S; Gostissa, M; Alt, FW. DNA repair, genome stability, and aging. Cell, 2005, 120, 497-512.
7. Balaban, RS; Nemoto, S; Finkel, T. Mitochondria, oxidants, and aging. Cell, 2005, 120, 483-95.
8. Betteridge, D. What is oxidative stress? Metabolism, 2000, 49, 3-8.
9. Reddy, PV; Murthy, Ch, R; Reddanna, P. Fulminant hepatic failure induced oxidative stress in nonsynaptic mitochondria of cerebral cortex in rats. Neurosci Lett, 2004, 368, 15-20.
10. Ciriolo, MR; Palamara, AT; Incerpi, S; Lafavia, E; Bue, MC; De Vito, P; Garaci, E; Rotilio, G. Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection. J Biol Chem, 1997, 272, 2700-8.
11. Qiang, W; Cahill, JM; Liu, J; Kuang, X; Liu, N; Scofield, VL; Voorhees, JR; Reid, AJ; Yan, M; Lynn, WS; Wong, PK. Activation of Transcription Factor Nrf-2 and Its Downstream Targets in Response to Moloney Murine Leukemia Virus ts1-Induced Thiol Depletion and Oxidative Stress in Astrocytes. J Virol, 2004, 78, 11926-38.
12. Reynolds, A; Laurie, C; Mosley, RL; Gendelman, HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol, 2007, 82, 297-325.
13. Nakamura, M; Shishido, N; Nunomura, A; Smith, MA; Perry, G; Hayashi, Y; Nakayama, K; Hayashi, T. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry, 2007, 46, 12737-43.
14. Bonda, DJ; Wang, X; Perry, G; Nunomura, A; Tabaton, M; Zhu, X; Smith, MA. Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology,
15. Henchcliffe, C; Beal, MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol, 2008, 4, 600-9.
16. Lin, W; Popko, B. Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci, 2009, 12, 379-85.
17. Vargas, MR; Johnson, DA; Sirkis, DW; Messing, A; Johnson, JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci, 2008, 28, 13574-81.
18. Turchan J, Gairola, PC; Chauhan, C; Schifitto, A; Butterfield, G; Buch, DA; Narayan, S; Sinai, O; Geiger, A; Berger, J; Elford, JR; Nath., HA. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology, 2003, 60, 307-14.
19. Mattson MPHN; Nath, A. Cell death in HIV dementia. Cell Death Differ, 2005, 12, 893-904.
20. Malorni, W; Rivabene, R; Lucia, BM; Ferrara, R; Mazzone, AM; Cauda, R; Paganelli, R. The role of oxidative imbalance in progression to AIDS: effect of the thiol supplier N-acetylcysteine. AIDS Res Hum Retroviruses, 1998 14, 1589-96.
21. Mollace, V; Nottet, HS; Clayette, P; Turco, MC; Muscoli, C; Salvemini, D; Perno, CF. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci, 2001, 24, 411-6.
22. Viviani, B; Corsini, E; Binaglia, M; Galli, CL; Marinovich, M. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience, 2001, 107, 51-8.
23. Antony, JM; van Marle, G; Opii, W; Butterfield, DA; Mallet, F; Yong, VW; Wallace, JL; Deacon, RM; Warren, K; Power, C. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci, 2004, 7, 1088-95.
24. Zhang, K; Kaufman, RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature, 2008, 454, 455-62.
25. Zhang, K; Kaufman, RJ. Identification and characterization of endoplasmic reticulum stress-induced apoptosis in vivo. Methods Enzymol, 2008, 442, 395-419.
26. Tu, BP; Weissman, JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol, 2004, 164, 341-6.
27. Tu, BP; Weissman, JS. The FAD-and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. Mol Cell, 2002, 10, 983-94.
28. Gross, E; Sevier, CS; Heldman, N; Vitu, E; Bentzur, M; Kaiser, CA; Thorpe, C; Fass, D. Generating disulfides enzymatically: reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p. Proc Natl Acad Sci, U S A, 2006, 103, 299-304.
29. Riemer, J; Bulleid, N; Herrmann, JM. Disulfide formation in the ER and mitochondria: two solutions to a common process. Science, 2009, 324, 1284-7.
30. Chakravarthi, S; Jessop, CE; Bulleid, NJ. The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep, 2006, 7, 271-5.
31. Ron, D; Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol, 2007, 8, 519-29.
32. Mezghrani, A; Fassio, A; Benham, A; Simmen, T; Braakman, I; Sitia, R. Manipulation of oxidative protein folding and PDI redox state in mammalian cells. EMBO J, 2001, 20, 6288-96.
33. Molteni, SN; Fassio, A; Ciriolo, MR; Filomeni, G; Pasqualetto, E; Fagioli, C; Sitia, R. Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum. J Biol Chem, 2004, 279, 32667-73.
34. Banhegyi, G; Benedetti, A; Csala, M; Mandl, J. Stress on redox. FEBS Lett, 2007, 581, 3634-40.
35. Cuozzo, JW; Kaiser, CA. Competition between glutathione and protein thiols for disulphide-bond formation. Nat Cell Biol, 1999, 1, 130-5.
36. Burchell, VS; Gandhi, S; Deas, E; Wood, NW; Abramov, AY; Plun-Favreau, H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opin Ther Targets, 14, 369-85.
37. Burchell, VS; Gandhi, S; Deas, E; Wood, NW; Abramov, AY; Plun-Favreau, H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part II. Expert Opin Ther Targets, 14, 497-511.
38. Shadel, GS. Expression and maintenance of mitochondrial DNA: new insights into human disease pathology. Am J Pathol, 2008, 172, 1445-56.
39. Bathori, G; Csordas, G; Garcia-Perez, C; Davies, E; Hajnoczky, G. Ca2+-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anion-selective channel (VDAC). J Biol Chem, 2006, 281, 17347-58.
40. Kroemer, G; Galluzzi, L; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol Rev, 2007, 87, 99-163.
41. Malhotra, JD; Kaufman, RJ. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol, 2007, 18, 716-31.
42. Liu, N; Kuang, X; Kim, HT; Stoica, G; Qiang, W; Scofield, VL; Wong, PK. Possible involvement of both endoplasmic reticulum-and mitochondria-dependent pathways in MoMuLV-ts1-induced apoptosis in astrocytes. J Neurovirol, 2004, 10, 189-98.
43. Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 1997, 19, 479-489.
44. Liu, NSV; Qiang, W, Yan, M, Kuang, X; Wong, PKY. Interaction between endoplasmic reticulum stress and caspase 8 activation in retrovirus MoMuLV-ts1-infected astrocytes. Virology, 2006, In print.
45. Bedard, K; Krause, KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 2007, 87, 245-313.
46. Park, L; Zhou, P; Pitstick, R; Capone, C; Anrather, J; Norris, EH; Younkin, L; Younkin, S; Carlson, G; McEwen, BS; Iadecola, C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci, U S A, 2008, 105, 1347-52.
47. Anantharam, V; Kaul, S; Song, C; Kanthasamy, A; Kanthasamy, AG. Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology, 2007, 28, 988-97.
48. Wu, DC; Re, DB; Nagai, M; Ischiropoulos, H; Przedborski, S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci, U S A, 2006, 103, 12132-7.
49. Marden, JJ; Harraz, MM; Williams, AJ; Nelson, K; Luo, M; Paulson, H; Engelhardt, JF. Redox modifier genes in amyotrophic lateral sclerosis in mice. J Clin Invest, 2007, 117, 2913-9.
50. Brennan, LA; Kantorow, M. Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res, 2009, 88, 195-203.
51. Chen, K; Kirber, MT; Xiao, H; Yang, Y; Keaney, JF, Jr. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol, 2008, 181, 1129-39.
52. Gandhi, S; Wood-Kaczmar, A; Yao, Z; Plun-Favreau, H; Deas, E; Klupsch, K; Downward, J; Latchman, DS; Tabrizi, SJ; Wood, NW; Duchen, MR; Abramov, AY. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell, 2009, 33, 627-38.
53. Johnson, JA; Johnson, DA; Kraft, AD; Calkins, MJ; Jakel, RJ; Vargas, MR; Chen, PC. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci, 2008, 1147, 61-9.
54. Kim, J; Cha, YN; Surh, YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res, 2009.
55. Vargas, MR; Johnson, JA. The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev Mol Med, 2009, 11, e17.
56. Ramsey, CP; Glass, CA; Montgomery, MB; Lindl, KA; Ritson, GP; Chia, LA; Hamilton, RL; Chu, CT; Jordan-Sciutto, KL. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol, 2007, 66, 75-85.
57. Kang, MI; Kobayashi, A; Wakabayashi, N; Kim, SG; Yamamoto, M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc Natl Acad Sci, U S A, 2004, 101, 2046-51.
58. Wakabayashi, N; Dinkova-Kostova, AT; Holtzclaw, WD; Kang, MI; Kobayashi, A; Yamamoto, M; Kensler, TW; Talalay, P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci, U S A, 2004, 101, 2040-5.
59. Winterbourn, CC; Hampton, MB. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med, 2008, 45, 549-61.
60. Shih, AY; Johnson, DA; Wong, G; Kraft, AD; Jiang, L; Erb, H; Johnson, JA; Murphy, TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci, 2003, 23, 3394-406.
61. Cullinan, SB; Zhang, D; Hannink, M; Arvisais, E; Kaufman, RJ; Diehl, JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol, 2003, 23, 7198-209.
62. Clements, CM; McNally, RS; Conti, BJ; Mak, TW; Ting, JP. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci, U S A, 2006, 103, 15091-6.
63. Canet-Aviles, RM; Wilson, MA; Miller, DW; Ahmad, R; McLendon, C; Bandyopadhyay, S; Baptista, MJ; Ringe, D; Petsko, GA; Cookson, MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci, U S A, 2004, 101, 9103-8.
64. Kanninen, K; Malm, TM; Jyrkkanen, HK; Goldsteins, G; Keksa-Goldsteine, V; Tanila, H; Yamamoto, M; Yla-Herttuala, S; Levonen, AL; Koistinaho, J. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci, 2008,
65. Calkins, MJ; Johnson, DA; Townsend, JA; Vargas, MR; Dowell, JA; Williamson, TP; Kraft, AD; Lee, JM; Li, J; Johnson, JA. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal, 2008.
66. Lavin, MF; Gueven, N; Bottle, S; Gatti, RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull, 2007, 81-82, 129-47.
67. McKinnon, PJ. ATM and ataxia telangiectasia. EMBO Rep, 2004, 5, 772-6.
68. Bakkenist, CJ; Kastan, MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature, 2003, 421, 499-506.
69. Kozlov, SV; Graham, ME; Peng, C; Chen, P; Robinson, PJ; Lavin, MF. Involvement of novel autophosphorylation sites in ATM activation. Embo J, 2006, 25, 3504-14.
70. Goodarzi, AA; Jonnalagadda, JC; Douglas, P; Young, D; Ye, R; Moorhead, GB; Lees-Miller, SP; Khanna, KK. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. Embo J, 2004, 23, 4451-61.
71. Burgoyne, JR; Madhani, M; Cuello, F; Charles, RL; Brennan, JP; Schroder, E; Browning, DD; Eaton, P. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science, 2007, 317, 1393-7.
72. Hunt, CR; Pandita, RK; Laszlo, A; Higashikubo, R; Agarwal, M; Kitamura, T; Gupta, A; Rief, N; Horikoshi, N; Baskaran, R; Lee, JH; Lobrich, M; Paull, TT; Roti Roti, JL; Pandita, TK. Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res, 2007, 67, 3010-7.
73. Stern, N; Hochman, A; Zemach, N; Weizman, N; Hammel, I; Shiloh, Y; Rotman, G; Barzilai, A. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. J Biol Chem, 2002, 277, 602-8.
74. Barzilai, A; Rotman, G; Shiloh, Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst), 2002, 1, 3-25.
75. Trushina, E; McMurray, CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience, 2007, 145, 1233-48.
76. Yi, M; Rosin, MP; Anderson, CK. Response of fibroblast cultures from ataxia-telangiectasia patients to oxidative stress. Cancer Lett, 1990 54, 43-50.
77. Kamsler, A; Daily, D; Hochman, A; Stern, N; Shiloh, Y; Rotman, G; Barzilai, A. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res, 2001, 61, 1849-54.
78. Barzilai, A; Yamamoto, K. DNA damage responses to oxidative stress. DNA Repair, (Amst), 2004, 3, 1109-15.
79. Takao, N; Li, Y; Yamamoto, K. Protective roles for ATM in cellular response to oxidative stress. FEBS Lett., 2000, 472, 133-6.
80. Liu, N; Stoica, G; Yan, M; Scofield, VL; Qiang, W; Lynn, WS; Wong, PK. ATM deficiency induces oxidative stress and endoplasmic reticulum stress in astrocytes. Lab Invest, 2005, 85, 1471-80.
81. Kim, J; Wong, PK. Oxidative Stress Is Linked to ERK1/2-p16 Signaling-mediated Growth Defect in ATM-deficient Astrocytes. J Biol Chem, 2009, 284, 14396-404.
82. Kim, J; Wong, PK. Loss of ATM Impairs Proliferation of Neural Stem Cells Through Oxidative Stress-Mediated p38 MAPK Signaling. Stem Cells, 2009, 27, 1987-1998.
83. Watters, DJ. Oxidative stress in ataxia telangiectasia. Redox Rep, 2003, 8, 23-9.
84. Peter, Y; Rotman, G; Lotem, J; Elson, A; Shiloh, Y; Groner, Y. Elevated Cu/Zn-SOD exacerbates radiation sensitivity and hematopoietic abnormalities of Atm-deficient mice. EMBO J, 2001, 20, 1538-46.
85. Yan, M; Zhu, C; Liu, N; Jiang, Y; Scofield, VL; Riggs, PK; Qiang, W; Lynn, WS; Wong, PK. ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state. Free Radic Biol Med, 2006, 41, 640-8.
86. Ito, K; Hirao, A; Arai, F; Matsuoka, S; Takubo, K; Hamaguchi, I; Nomiyama, K; Hosokawa, K; Sakurada, K; Nakagata, N; Ikeda, Y; Mak, TW; Suda, T. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature, 2004, 431, 997-1002.
87. Matsuoka, S; Ballif, BA; Smogorzewska, A; McDonald, ER, 3rd; Hurov, KE; Luo, J; Bakalarski, CE; Zhao, Z; Solimini, N; Lerenthal, Y; Shiloh, Y; Gygi, SP; Elledge, SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science, 2007, 316, 1160-6.
88. Soutoglou, E; Misteli, T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science, 2008, 320, 1507-10.
89. Schneider, JG; Finck, BN; Ren, J; Standley, KN; Takagi, M; Maclean, KH; Bernal-Mizrachi, C; Muslin, AJ; Kastan, MB; Semenkovich, CF. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab, 2006, 4, 377-89.
90. Yan, M; Shen, J; Person, MD; Kuang, X; Lynn, WS; Atlas, D; Wong, PK. Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress. Neoplasia, 2008, 10, 160-7.
91. He, X; Chen, MG; Ma, Q. Activation of Nrf2 in defense against cadmium-induced oxidative stress. Chem Res Toxicol, 2008, 21, 1375-83.
92. Eaton, JS; Lin, ZP; Sartorelli, AC; Bonawitz, ND; Shadel, GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest, 2007, 117, 2723-34.
93. Ambrose, M; Goldstine, JV; Gatti, RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet, 2007, 16, 2154-64.
94. Saito, S; Goodarzi, AA; Higashimoto, Y; Noda, Y; Lees-Miller, SP; Appella, E; Anderson, CW. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem, 2002, 277, 12491-4.
95. Matoba, S; Kang, JG; Patino, WD; Wragg, A; Boehm, M; Gavrilova, O; Hurley, PJ; Bunz, F; Hwang, PM. p53 regulates mitochondrial respiration. Science, 2006, 312, 1650-3.
96. Donahue, RJ; Razmara, M; Hoek, JB; Knudsen, TB. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB J, 2001, 15, 635-44.
97. Torroglosa, A; Murillo-Carretero, M; Romero-Grimaldi, C; Matarredona, ER; Campos-Caro, A; Estrada, C. Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway. Stem Cells, 2007, 25, 88-97.
98. Gage, FH. Mammalian neural stem cells. Science, 2000, 287, 1433-8.
99. Allen, DM; van Praag, H; Ray, J; Weaver, Z; Winrow, CJ; Carter, TA; Braquet, R; Harrington, E; Ried, T; Brown, KD; Gage, FH; Barlow, C. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes & Development, 2001, 15, 554-66.
100. Gosink, EC; Chong, MJ; McKinnon, PJ. Ataxia telangiectasia mutated deficiency affects astrocyte growth but not radiosensitivity. Cancer Res., 1999 59, 5294-8.
101. Liu, J; Cao, L; Chen, J; Song, S; Lee, IH; Quijano, C; Liu, H; Keyvanfar, K; Chen, H; Cao, LY; Ahn, BH; Kumar, NG; Rovira, II; Xu, XL; van Lohuizen, M; Motoyama, N;Deng, CX; Finkel, T. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature, 2009, 459, 387-92.
102. Chatoo, W; Abdouh, M; David, J; Champagne, MP; Ferreira, J; Rodier, F; Bernier, G. The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci, 2009, 29, 529-42.
103. Leung, C; Lingbeek, M; Shakhova, O; Liu, J; Tanger, E; Saremaslani, P; Van Lohuizen, M; Marino, S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature, 2004, 428, 337-41.
104. He, S; Iwashita, T; Buchstaller, J; Molofsky, AV; Thomas, D; Morrison, SJ. Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo. Dev Biol, 2009, 328, 257-72.
105. Voncken, JW; Niessen, H; Neufeld, B; Rennefahrt, U; Dahlmans, V; Kubben, N; Holzer, B; Ludwig, S; Rapp, UR. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J Biol Chem, 2005, 280, 5178-87.
106. Davila, D; Torres-Aleman, I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell, 2008, 19, 2014-25.
107. Golding, SE; Rosenberg, E; Valerie, N; Hussaini, I; Frigerio, M; Cockcroft, XF; Chong, WY; Hummersone, M; Rigoreau, L; Menear, KA; O'Connor, MJ; Povirk, LF; van Meter, T; Valerie, K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther, 2009, 8, 2894-902.
108. Marx, J. Alzheimer's disease. A new take on tau. Science, 2007, 316, 1416-7.
109. Le Corre, S; Klafki, HW; Plesnila, N; Hubinger, G; Obermeier, A; Sahagun, H; Monse, B; Seneci, P; Lewis, J; Eriksen, J; Zehr, C; Yue, M; McGowan, E; Dickson, DW; Hutton, M; Roder, HM. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci, U S A, 2006, 103, 9673-8.
110. Chu, CT; Levinthal, DJ; Kulich, SM; Chalovich, EM; DeFranco, DB. Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem, 2004, 271, 2060-6.
111. Nyati, MK; Feng, FY; Maheshwari, D; Varambally, S; Zielske, SP; Ahsan, A; Chun, PY; Arora, VA; Davis, MA; Jung, M; Ljungman, M; Canman, CE; Chinnaiyan, AM; Lawrence, TS. Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. Cancer Res, 2006, 66, 11554-9.
112. Han, J; Tsukada, Y; Hara, E; Kitamura, N; Tanaka, T. Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem, 2005, 280, 31548-56.
113. Pardal, R; Molofsky, AV; He, S; Morrison, SJ. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol, 2005, 70, 177-85.
114. Sharpless, NE; DePinho, RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol, 2007, 8, 703-13.
115. Webber, KM; Smith, MA; Lee, HG; Harris, PL; Moreira, P; Perry, G; Zhu, X. Mitogen-and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease. J Neurosci Res, 2005, 79, 554-60.
116. Cerimele, F; Battle, T; Lynch, R; Frank, DA; Murad, E; Cohen, C; Macaron, N; Sixbey, J; Smith, K; Watnick, RS; Eliopoulos, A; Shehata, B; Arbiser, JL. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci, U S A, 2005, 102, 175-9.
117. Cho, HY; Imani, F; Miller-DeGraff, L; Walters, D; Melendi, GA; Yamamoto, M; Polack, FP; Kleeberger, SR. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med, 2009, 179, 138-50.
118. Kumar, S; Kalita, J; Saxena, V; Khan, MY; Khanna, VK; Sharma, S; Dhole, TN; Misra, UK. Some observations on the tropism of Japanese encephalitis virus in rat brain. Brain Res, 2009, 1268, 135-41.
119. Kumar, S; Misra, UK; Kalita, J; Khanna, VK; Khan, MY. Imbalance in oxidant/antioxidant system in different brain regions of rat after the infection of Japanese encephalitis virus. Neurochem Int, 2009, 55, 648-54.
120. Mishra, MK; Ghosh, D; Duseja, R; Basu, A. Antioxidant potential of Minocycline in Japanese Encephalitis Virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int, 2009, 54, 464-70.
121. Bautista, AP. Free radicals, chemokines, and cell injury in HIV-1 and SIV infections and alcoholic hepatitis. Free Radic Biol Med, 2001, 31, 1527-32.
122. Webb, C; Lehman, T; McCord, K; Avery, P; Dow, S. Oxidative stress during acute FIV infection in cats. Vet Immunol Immunopathol, 2008, 122, 16-24.
123. Gonzales-Scarano, F; Nathanson, N; Wong, PKY. Retroviruses and the nervous system. In: Levy JA, ed. The Retroviridae, vol 4. New York, NY, Plenum Press; 1995, 409-490.
124. Lynn, WS; Wong, PKY. Neuroimmunodegeneration: Do neurons and T cells utilize common pathways for cell death? FASEB J., 1995, 9, 1147-1156.
125. Antony, JM; Zhu, Y; Izad, M; Warren, KG; Vodjgani, M; Mallet, F; Power, C. Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis. AIDS Res Hum Retroviruses, 2007, 23, 1251-6.
126. Lombardi, VC; Ruscetti, FW; Das Gupta, J; Pfost, MA; Hagen, KS; Peterson, DL; Ruscetti, SK; Bagni, RK; Petrow-Sadowski, C; Gold, B; Dean, M; Silverman, RH; Mikovits, JA. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science, 2009, 326, 585-9.
127. Wong, PKY. Moloney murine leukemia virus temperature-sensitive mutants: A model for retrovirus-induced neurologic disorders. Curr. Top. Microbiol. Immunol., 1990, 160, 29-60.
128. Kaiser, J. AIDS research. Review of vaccine failure prompts a return to basics. Science, 2008, 320, 30-1.
129. Gardener, MB; Henderson, BE; Officer, JE; Rongey, RW; Parker, JD; Oliver, C; Estes, JD; Huebner, RJ. A spontaneous lower motor neuron disease apparently caused by indigenous type-C RNA virus in wild mice. J. Natl. Cancer Inst., 1973 51, 1243-1249.
130. Portis, JL; Askovich, P; Austin, J; Gutierrez-Cotto, Y; McAtee, FJ. The degree of folding instability of the envelope protein of a neurovirulent murine retrovirus correlates with the severity of the neurological disease. J Virol, 2009, 83, 6079-86.
131. Paquette, Y; Hanna, Z; Savard, P; Brousseau, R; Robitaille, Y; Jolicoeur, P. Retrovirus-induced murine motor neuron disease: Mapping the determinant of spongiform degeneration with the envelope gene. Proc. Natl. Acad. Sci., USA, 1989 86, 3896-3900.
132. Wong, PKY; Yuen, PH. Molecular basis of neurologic disorders induced by a mutant, ts1, of Moloney murine leukemia virus. In: Roos RP, (ed.) Molecular Neurovirology: Pathogenesis of Viral CNS Infection,vol Totowa, New Jersey, Humana Press; 1992; 161-197.
133. Szurek, PF; Yuen, PH; Jerzy, R; Wong, PKY. Identification of point mutations in the envelope gene of Moloney murine leukemia virus TB temperature-sensitive paralytogenic mutant ts1: Molecular determinants for neurovirulence. J. Virol., 1988, 62, 357-360.
134. Shikova, E; Lin, YC; Saha, K; Brooks, BR; Wong, PK. Correlation of specific virus-astrocyte interactions and cytopathic effects induced by ts1, a neurovirulent mutant of Moloney murine leukemia virus. J Virol, 1993, 67, 1137-47.
135. Wong, PKY; Lynn, WS. Neuroimmunodegeneration syndromes: definition and models. In: Wong PKY, Lynn WS, (eds.) Neuroimmunodegeneration,vol Heidelberg, R.G. Landes; 1998, 29-50.
136. Wong, PKY; Lynn, WS; Lin, YC; Choe, W; Yuen, PH. ts1 MoMuLV: A murine model of neuroimmunodegeneration. In: Wong PKY, Lynn WS, (eds.) Neuroimmuno-degeneration,vol Austin, R.G. Landes; 1998, 75-93.
137. Clark, S; Duggan, J; Chakraborty, J. Tsl and LP-BM5: a comparison of two murine retrovirus models for HIV. Viral Immunol, 2001, 14, 95-109.
138. Saha K, YP, and PKY Wong. Murine retrovirus-induced depletion of T cells is mediated through activation-induced death by apoptosis. J Virol, 1994 68, 2735-40.
139. Wong, PK; Prasad, G; Hansen, J; Yuen, PH. ts1, a mutant of Moloney murine leukemia virus-TB, causes both immunodeficiency and neurologic disorders in BALB/c mice. Virology, 1989, 170, 450-9.
140. Salmen S, GC, Colmenares M, Barboza L, Goncalves L, Teran G, Alfonso N, Montes H, and L Berrueta. Role of human immunodeficiency virus in leukocytes apoptosis from infected patients. Invest Clin, 2005, 46, 289-305.
141. Stoica, G; Illanes, O; Tasca, SI; Wong, PKY. Temporal central and peripheral nervous system changes induced by a paralytogenic mutant of Moloney murine leukemia virus TB. Lab Invest, 1993, 66, 427-436.
142. Stoica, G; Tasca, SI; Wong, PKY. Motor neuronal loss and neurofilament-ubiquitin alteration in MoMuLV-ts1 encephalopathy. Acta Neuropathol, (Berl), 2000, 99, 238-244.
143. Sabri, F; Titanji, K; De Milito, A; Chiodi, F. Astrocyte activation and apoptosis: their roles in the neuropathology of HIV infection. Brain Pathol, 2003, 13, 84-94.
144. Lindl, KA; Akay, C; Wang, Y; White, MG; Jordan-Sciutto, KL. Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropathol Appl Neurobiol, 2007, 33, 658-69.
145. Jana, AaKP. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci, 2004, 24, 9531-40.
146. Pollicita, M; Muscoli, C; Sgura, A; Biasin, A; Granato, T; Masuelli, L; Mollace, V; Tanzarella, C; Del Duca, C; Rodino, P; Perno, CF; Aquaro, S. Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. BMC Neurosci, 2009, 10, 51.
147. Ronaldson, PT; Bendayan, R. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells. J Neurochem, 2008, 106, 1298-313.
148. Ozdener, H. Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci, 2005, 30, 391-405.
149. Thompson, KA; McArthur, JC; Wesselingh, SL. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol, 2001, 49, 745-52.
150. Stoica, G; Floyd, E; Illanes, O; Wong, PKY. Temporal lymphoreticular changes caused by ts1, a paralytogenic mutant of Moloney murine leukemia virus-TB. Lab. Invest., 1992, 66, 427-436.
151. An, SF; Groves, M; Gray, F; Scaravilli, F. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol, 1999 58, 1156-62.
152. Poland, SD; Rice, GP; Dekaban, GA. HIV-1 infection of human brain-derived microvascular endothelial cells in vitro. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 8, 437-45.
153. Zachary, JF; Baszler, TV; French, RA; Kelley, KW. Mouse Moloney leukemia virus infects microglia but not neurons even though it induces motor neuron disease. Mol Psychiatry, 1997, 2, 104-106.
154. Choe, WK; Stoica, G; Lynn, WS; Wong, PKY. Neurodegeneration induced by MoMuLV-ts1 and increased expression of TNFa and Fas in the central nervous system. Brain Res., 1998, 779, 1-8.
155. Blumberg, BM; Gelbard, HA; Epstein, LG. HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis. Virus Res., 1994 32, 253-67.
156. Pulliam, L; West, BS; Haigwood, N; Swanson, RA. HIV-1 envelope gp120 alters astrocytes in human brain culture. AIDS Res. Hum. Retro., 1993, 9, 439-444.
157. Kim, HT; Qiang, W; Wong, PK; Stoica, G. Enhanced proteolysis of IkappaBalpha and IkappaBbeta proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)-ts1 infection: a potential mechanism of NF-kappaB activation. J Neurovirol, 2001, 7, 466-475.
158. Chen, W; Sulcove, J; Frank, I; Jaffer, S; Ozdener, H; Kolson, DL. Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway. J Virol, 2002, 76, 9407-19.
159. Jolicoeur P, HC, Mak TW, Martinou JC, and DG Kay. Protection against murine leukemia virus-induced spongiform myeloencephalopathy in mice overexpressing Bcl-2 but not in mice deficient for interleukin-6, inducible nitric oxide synthetase, ICE, Fas, Fas ligand, or TNF-R1 genes. J Virol, 2003, 77, 13161-70.
160. Kim, HT; Tasca, S; Qiang, W; Wong, PK; Stoica, G. Induction of p53 accumulation by Moloney murine leukemia virus-ts1 infection in astrocytes via activation of extracellular signal-regulated kinases 1/2. Lab Invest, 2002, 82, 693-702.
161. Qiang, W; Kuang, X; Liu, J; Liu, N; Scofield, V; Stoica, G; Lynn, WS; Wong, PKY. Astrocytes survive chronic infection and cytopathic effects of the ts1 mutant of the retrovirus Moloney murine leukemia virus by upregulation of antioxidant defenses. J Virol, 2006, 80, 3273-84.
162. Fenouillet, E; Barbouche, R; Jones, IM. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Signal, 2007, 9, 1009-34.
163. Lavillette, D; Barbouche, R; Yao, Y; Boson, B; Cosset, FL; Jones, IM; Fenouillet, E. Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV envelope. J Biol Chem, 2006, 281, 9200-4.
164. Ryser, HJP; Levy, EM; Mandel, R; DiSciullo, GJ. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc. Natl. Acad. Sci., USA, 1994, 91, 4559-4563.
165. Ryser, HJ; Levy, EM; Mandel, R; DiSciullo, GJ. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci, U S A, 1994 91, 4559-63.
166. Markovic, I; Stantchev, TS; Fields, KH; Tiffany, LJ; Tomic, M; Weiss, CD; Broder, CC; Strebel, K; Clouse, KA. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood, 2004, 103, 1586-94.
167. Jiang, Y; Scofield, VL; Yan, M; Qiang, W; Liu, N; Reid, AJ; Lynn, WS; Wong, PK. Retrovirus-induced oxidative stress with neuroimmunodegeneration is suppressed by antioxidant treatment with a refined monosodium alpha-luminol (Galavit). J Virol, 2006, 80, 4557-69.
168. Scofield, VL; Yan, M; Kuang, X; Kim, SJ; Crunk, D; Wong, PK. The drug monosodium luminol (GVT) preserves thymic epithelial cell cytoarchitecture and allows thymocyte survival in mice infected with the T cell-tropic, cytopathic retrovirus ts1. Immunol Lett, 2009, 122, 159-69.
169. Scofield, VL; Yan, M; Kuang, X; Kim, SJ; Wong, PK. The drug monosodium luminol (GVT) preserves crypt-villus epithelial organization and allows survival of intestinal T cells in mice infected with the ts1 retrovirus. Immunol Lett, 2009, 122, 150-8.
170. Lynn, WS; Wong, PKY. Neuroimmunopathogenesis of ts1 MoMuLV infection. Neuroimmunomodulation, 1998 5, 248-260.
171. Lozano, GaGZ. What have animal models taught us about the p53 pathway? J Pathol, 2005, 205, 206-20.
172. Sacktor N, HN, Cutler R, Tamara A, Turchan J, Pardo C, Vargas D, and A Nath. Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol., 2004, 157, 176-84.
173. Price, TO; Uras, F; Banks, WA; Ercal, N. A novel antioxidant N-acetylcysteine amide prevents gp120-and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol, 2006, 201, 193-202.
174. Steiner, J; Haughey, N; Li, W; Venkatesan, A; Anderson, C; Reid, R; Malpica, T; Pocernich, C; Butterfield, DA; Nath, A. Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal, 2006, 8, 2089-100.
175. Kruman, II; Nath, A; Mattson, MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Experimental Neurology, 1998, 154, 276-288.
176. Valcour, V; Shiramizu, B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion, 2004, 4, 119-29.
177. Kuang, X; Scofield, VL; Yan, M; Stoica, G; Liu, N; Wong, PK. Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res, 2009, 1286, 174-84.
178. Treitinger, A; Spada, C; Verdi, JC; Miranda, AF; Oliveira, OV; Silveira, MV; Moriel, P; Abdalla, DS. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. European Journal of Clinical Investigation, 2000, 30, 454-459.
179. Suresh, DR; Annam, V; Pratibha, K; Prasad, BV. Total antioxidant capacity--a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci, 2009, 16, 61.
180. Norman, JP; Perry, SW; Reynolds, HM; Kiebala, M; De Mesy Bentley, KL; Trejo, M; Volsky, DJ; Maggirwar, SB; Dewhurst, S; Masliah, E; Gelbard, HA. HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One, 2008, 3, e3731.
181. Liu, N; Scofield, VL; Qiang, W; Yan, M; Kuang, X; Wong, PK. Interaction between endoplasmic reticulum stress and caspase 8 activation in retrovirus MoMuLV-ts1-infected astrocytes. Virology, 2006, 348, 398-405.
182. Kim, HT; Waters, K; Stoica, G; Qiang, W; Liu, N; Scofield, VL; Wong, PK. Activation of endoplasmic reticulum stress signaling pathway is associated with neuronal degeneration in MoMuLV-ts1-induced spongiform encephalomyelopathy. Lab Invest, 2004, 84, 816-27.
183. Haughey, N; Mattson, M. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr, 2002, 31, S55-61.
184. Norman, JP; Perry, SW; Kasischke, KA; Volsky, DJ; Gelbard, HA. HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons. J Immunol, 2007, 178, 869-76.
185. Wojda, U; Salinska, E; Kuznicki, J. Calcium ions in neuronal degeneration. IUBMB Life, 2008, 60, 575-90.
186. Nardacci R, AA, Larocca LM, Arena V, Amendola A, Perfettini JL, Kroemer G, and M Piacentini. Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis. Am J Pathol, 2005, 167, 695-704.
187. Bridges CC, HH, Miyauchi S, Siddaramappa UN, Ganapathy ME, Ignatowicz L, Maddox DM, Smith SB, and V Ganapathy. Induction of cystine-glutamate transporter xc-by human immunodeficiency virus type 1 transactivator protein tat in retinal pigment epithelium. Invest Ophthalmol Vis Sci, 2004, 45, 2906-14.
188. Achim, CL; Adame, A; Dumaop, W; Everall, IP; Masliah, E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol, 2009, 4, 190-9.
189. Esiri, MM; Biddolph, SC; Morris, CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry, 1998 65, 29-33.
190. Rempel, HC; Pulliam, L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS, 2005, 19, 127-35.
191. Pulliam, L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol, 2009, 4, 213-7.
192. An, SF; Scaravilli, F. Early HIV-1 infection of the central nervous system. Arch Anat Cytol Pathol, 1997, 45, 94-105.
193. Wu, RF; Ma, Z; Myers, DP; Terada, LS. HIV-1 Tat activates dual Nox pathways leading to independent activation of ERK and JNK MAP kinases. J Biol Chem, 2007, 282, 37412-9.
194. Adamson, DC; Wildemann, B; Sasaki, M; Glass, JD; McArthur, JC; Christov, VI; Dawson, TM; Dawson, VL. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science, 1996, 274, 1917-21.
195. Alvarez, S; Serramia, MJ; Fresno, M; Munoz-Fernandez, M. Human immunodeficiency virus type 1 envelope glycoprotein 120 induces cyclooxygenase-2 expression in neuroblastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism. J Neurochem, 2005, 94, 850-61.
196. Kim, HT; Qiang, W; Liu, N; Scofield, VL; Wong, PK; Stoica, G. Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein-homology protein, glucose-related protein 78, eukaryotic initiation factor 2 alpha, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus. J Neurovirol, 2005, 11, 166-79.
197. Opalenik, SR; Ding, Q; Mallery, SR; Thompson, JA. Glutathione depletion associated with the HIV-1 TAT protein mediates the extracellular appearance of acidic fibroblast growth factor. Arch Biochem Biophys, 1998 351, 17-26.
198. Stoica, G; Lungu, G; Kim, HT; Wong, PK. Up-regulation of pro-nerve growth factor, neurotrophin receptor p75, and sortilin is associated with retrovirus-induced spongiform encephalomyelopathy. Brain Res, 2008, 1208, 204-16.
199. Zhang, HS; Li, HY; Zhou, Y; Wu, MR; Zhou, HS. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic Biol Med, 2009, 47, 261-8.
200. Kline, ER; Kleinhenz, DJ; Liang, B; Dikalov, S; Guidot, DM; Hart, CM; Jones, DP; Sutliff, RL. Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am J Physiol Heart Circ Physiol, 2008, 294, H2792-804.
201. Zink, MC; UJ, DeWitt, J; Voelker, T; Bullock, B; Mankowski, J; Tarwater, P; Clements, J; Barber, S. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA, 2005, 293, 2003,-11.
202. Visalli, V; Muscoli, C; Sacco, I; Sculco, F; Palma, E; Costa, N; Colica, C; Rotiroti, D; Mollace, V. N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction. BMC Neurosci, 2007, 8, 106.
203. Churchill, MJ; Wesselingh, SL; Cowley, D; Pardo, CA; McArthur, JC; Brew, BJ; Gorry, PR. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol, 2009, 66, 253-8.
204. Borjabad, A; Brooks, AI; Volsky, DJ. Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol, 5, 44-62.
205. Wong, PKY; Yuen, PH. Cell types in the central nervous system infected by murine retroviruses: Implications for the mechanisms of neurodegeneration. Histol. Histopathol., 1994, 9, 845-848.
206. Walmsley, SL; Winn, LM; Harrison, ML; Uetrecht, JP; Wells, PG. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. Aids, 1997, 11, 1689-97.
207. Pace, GW; Leaf, CD. The role of oxidative stress in HIV disease. Free Radical Biology & Medicine, 1995, 19, 523-528.
208. Chauhan, ATJ; Pocernich, C; Bruce-Keller, A; Roth, S; Butterfield, DA; Major, EO, and A Nath. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem, 2003, 278, 13512-9.
209. Haughey, NJCR; Tamara, A; McArthur, JC; Vargas, DL; Pardo, CA; Turchan, J; Nath, A; Mattson, MP. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol, 2004, 55, 257-67.
210. Toborek, M; Lee, YW; Pu, H; Malecki, A; Flora, G; Garrido, R; Hennig, B; Bauer, HC; Nath, A. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem, 2003, 84, 169-79.
211. Paschen, W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium, 2001, 29, 1-11.
212. Sherman, MY; Goldberg, AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 2001, 29, 15-32.
213. Sitia, R; Molteni, SN. Stress, protein (mis)folding, and signaling: the redox connection. Sci STKE, 2004, pe27.
214. Jacob, C; Giles, GI; Giles, NM; Sies, H. Sulfur and selenium: the role of oxidation state in protein structure and function. Angew Chem Int Ed Engl, 2003, 42, 4742-58.
215. Bates, GP. Biomedicine: One misfolded protein allows others to sneak by., 2006, 311, 1385-6.
216. Gidalevitz, T; Ben-Zvi, A; Ho, K; Brignull, H; Morimoto, R. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science, 2006, 311, 1471-4.
217. Ushioda, R; Hoseki, J; Araki, K; Jansen, G; Thomas, DY; Nagata, K. ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER. Science, 2008, 321, 569-72.
218. Ilieva, EV; Ayala, V; Jove, M; Dalfo, E; Cacabelos, D; Povedano, M; Bellmunt, MJ; Ferrer, I; Pamplona, R; Portero-Otin, M. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain, 2007, 130, 3111-23.
219. Miller, G. Neurodegeneration. Could they all be prion diseases? Science, 2009, 326, 1337-9.
220. Land, A; Braakman, I. Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie, 2001, 83, 783-90.
221. Earl, PL; Moss, B; Doms, RW. Folding, interaction with the GRP78-BiP, assembly and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol., 1991, 65, 2047-2055.
222. Koga, Y; Sasaki, M; Nskamura, K. Intracellular distribution of the envelope glycoprotein of human immunodeficiency virus type 1 and its role in the production of cytopathic effect in CD4+ and CD4-human cell line. J. Virol., 1990, 46, 4661-4671.
223. Crise, B; Rose, JK. Human immunodeficiency virus type 1 glycoprotein precursor retains a CD4-P56 complex in the endoplasmic reticulum. J. Virol., 1992, 66, 2296-2301.
224. Jobes, DV; Daoust, M; Nguyen, V; Padua, A; Michele, S; Lock, MD; Chen, A; Sinangil, F; Berman, PW. High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial. AIDS Res Hum Retroviruses, 2006, 22, 1014-21.
225. Zhou, H; Pandak, WM, Jr.; Lyall, V; Natarajan, R; Hylemon, PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol, 2005, 68, 690-700.
226. Wong, PKY; Lynn, WS. Neuroimmunodegeneration. EOS J. Immunol. Immunopharmacol., 1997, 17, 30-35.
227. Chen, Y; Vartiainen, NE; Ying, W; Chan, PH; Koistinaho, J; Swanson, RA. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem, 2001, 77, 1601-10.
228. Wang, Z; Trillo-Pazos, G; Kim, SY; Canki, M; Morgello, S; Sharer, LR; Gelbard, HA; Su, ZZ; Kang, DC; Brooks, AI; Fisher, PB; Volsky, DJ. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol, 2004, 10 Suppl 1, 25-32.
229. Wang, T; Gong, N; Liu, J; Kadiu, I; Kraft-Terry, SD; Mosley, RL; Volsky, DJ; Ciborowski, P; Gendelman, HE. Proteomic modeling for HIV-1 infected microglia-astrocyte crosstalk. PLoS ONE, 2008, 3, e2507.
230. Trillo-Pazos, G; Diamanturos, A; Rislove, L; Menza, T; Chao, W; Belem, P; Sadiq, S; Morgello, S; Sharer, L; Volsky, DJ. Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol, 2003, 13, 144-54.
231. Li, J; Bentsman, G; Potash, MJ; Volsky, DJ. Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection. BMC Neurosci, 2007, 8, 31.
232. Cosenza-Nashat, MA; Si, Q; Zhao, ML; Lee, SC. Modulation of astrocyte proliferation by HIV-1: differential effects in productively infected, uninfected, and Nef-expressing cells. J Neuroimmunol, 2006, 178, 87-99.
233. Kim, SY; Li, J; Bentsman, G; Brooks, AI; Volsky, DJ. Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: implications for HAD. J Neuroimmunol, 2004, 157, 17-26.
234. Dou, H; Morehead, J; Bradley, J; Gorantla, S; Ellison, B; Kingsley, J; Smith, LM; Chao, W; Bentsman, G; Volsky, DJ; Gendelman, HE. Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain. Glia, 2006, 54, 81-93.
235. Nath, A. Pathobiology of human immunodeficiency virus dementia. Semin Neurol, 1999, 19, 113-27.
236. Patton, HKZZ; Bubien, JK; Benveniste, EN; Benos, DJ. gp120-induced alterations of human astrocyte function: Na(+)/H(+) exchange, K(+) conductance, and glutamate flux. Am J Physiol Cell Physiol, 2000, 279, C700-8.
237. Pocernich, CBSR; Mohmmad-Abdul, H; Nath, A; Butterfield, DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Rev, 2005, 50, 14-26.
238. Cinque, PRK; Antinori, A; Price, RW. Neurological complications of HIV infection and AIDS: Current and future perspectives. J Neurovirol., 2005, 11, 1-5.
239. Jones, G; Power, C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis, 2006, 21, 1-17.
240. Thompson, PMDR; Hayashi, KM; Toga, AW; Lopez, OL; Aizenstein, HJ; Becker, JT. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. PNAS, 2005, 102, 15647-52.
241. Grinberg, L; Fibach, E; Amer, J; Atlas, D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic Biol Med, 2005, 38, 136-45.
242. Offen, D; Gilgun-Sherki, Y; Barhum, Y; Benhar, M; Grinberg, L; Reich, R; Melamed, E; Atlas, D. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem, 2004, 89, 1241-51.
243. Gross, S; Gammon, ST; Moss, BL; Rauch, D; Harding, J; Heinecke, JW; Ratner, L; Piwnica-Worms, D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med, 2009, 15, 455-61.
244. Sanders, JM; Chen, LJ; Burka, LT; Matthews, HB. Metabolism and disposition of luminol in the rat. Xenobiotica, 2000, 30, 263-72.
245. Reddy, PV; Lungu, G; Kuang, X; Stoica, G; Wong, PK. Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytes. Neurochem Int, 56:780-8.
246. Qiang, W; Liu, J; Ren, D; Wong, PKY; Lynn, WS; Miller, RJ. Monosodium luminol (GVT), a modulator of activated microglia, is a potential treatment for neurodegenerative diseases. In Neuroscience 2008,vol Washington, DC, 312.3; 2008,.
247. Lungu, GF; Kuang, X; Stoica, G; Y., Wong PK. Monosodium luminol upregulates the expression of Bcl-2 and VEGF in retrovirus-infected mice, through downregulation of corresponding miRNAs. Acta Virologica, 2010, 54.
248. Bartov O, SR, Butterfield DA, and D Atlas. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity. Brain Res, 2006, 1069, 198-206.
249. Bahat-Stroomza, M; Gilgun-Sherki, Y; Offen, D; Panet, H; Saada, A; Krool-Galron, N; Barzilai, A; Atlas, D; Melamed, E. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur J Neurosci, 2005, 21, 637-46.
250. Reliene, R; Fleming, SM; Chesselet, MF; Schiestl, RH. Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice. Food Chem Toxicol, 2008, 46, 1371-7.
251. Browne, SE; Roberts, LJ, 2nd; Dennery, PA; Doctrow, SR; Beal, MF; Barlow, C; Levine, RL. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med, 2004, 36, 938-42.
252. Schubert, R; Erker, L; Barlow, C; Yakushiji, H; Larson, D; Russo, A; Mitchell, JB; Wynshaw-Boris, A. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet, 2004, 13, 1793-802.
253. Gueven, N; Luff, J; Peng, C; Hosokawa, K; Bottle, SE; Lavin, MF. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in Atm-mutant mice with a nitroxide antioxidant. Free Radic Biol Med, 2006, 41, 992-1000.
254. Hotamisligil, GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med, 16, 396-9.
255. Balch, WE; Morimoto, RI; Dillin, A; Kelly, JW. Adapting proteostasis for disease intervention. Science, 2008, 319, 916-9.
256. Ozcan, U; Yilmaz, E; Ozcan, L; Furuhashi, M; Vaillancourt, E; Smith, RO; Gorgun, CZ; Hotamisligil, GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 2006, 313, 1137-40.
257. Geller, R; Vignuzzi, M; Andino, R; Frydman, J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev, 2007, 21, 195-205.
258. Liu, N; Qiang, W; Kuang, X; Thuillier, P; Lynn, WS; Wong, PK. The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death. J Neurovirol, 2002, 8, 318-325.
259. Jejcic, A; Daniels, R; Goobar-Larsson, L; Hebert, DN; Vahlne, A. Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation. J Virol, 2009, 83, 10075-84.
260. Lee, JP; Jeyakumar, M; Gonzalez, R; Takahashi, H; Lee, PJ; Baek, RC; Clark, D; Rose, H; Fu, G; Clarke, J; McKercher, S; Meerloo, J; Muller, FJ; Park, KI; Butters, TD; Dwek, RA; Schwartz, P; Tong, G; Wenger, D; Lipton, SA; Seyfried, TN; Platt, FM; Snyder, EY. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med, 2007, 13, 439-47.
261. Parker, MA; Anderson, JK; Corliss, DA; Abraria, VE; Sidman, RL; Park, KI; Teng, YD; Cotanche, DA; Snyder, EY. Expression profile of an operationally-defined neural stem cell clone. Exp Neurol, 2005, 194, 320-32.
262. Li, J; Imitola, J; Snyder, EY; Sidman, RL. Neural stem cells rescue nervous purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets. J Neurosci, 2006, 26, 7839-48.
263. Lo SC, Pripuzova N, Li B, Komaroff AL, Hung GC, Wang R, Alter HJ. Detectio of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. PNAS, 2010, epub ahead of print.
264. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. JCB, 2004, 164, 341-346
265. Kuang X, Hu W, Yan M and Wong PK. Phenylbutyric acid suppresses protein accumulation-mediated ER stress in retrovirus-infected astrocytes and delays onset of paralysis in infected mice. Neurochem Int. 2010. In press.